Avenzo Therapeutics

Today, we announced the appointment of Patrick Machado, J.D. to our Board of Directors. Mr. Machado’s more than 20 years of global #biotech management and board experience will be highly beneficial as we continue to build and advance our pipeline of #oncology therapies to help patients fight #cancers with a high unmet medical need.?? ? Read the full press release: https://bit.ly/3CLqW2q

Exclusive: Avenzo Therapeutics is joining the growing trend of US biotechs in-licensing assets from China-based drug developers as the San Diego startup has inked a deal for VelaVigo's Nectin-4/TROP2 bispecific antibody-drug conjugate. Avenzo also brought in an additional ~$39 million and promoted Scott Lipman to chief business officer. Avenzo is searching for more ADCs as it plans to have multiple experimental medicines in the clinic next year ahead of a potential IPO in late 2025 or early 2026, CEO Athena Countouriotis told Endpoints News #adc #antibodydrugconjugate #biotech #licensingdeal #chinabiotech #nectin4 #trop2 #oncologydrugdevelopment #avenzo #velavigo

Today marks an important step in our growth as we announce the closing of the final tranche of a Series A/A-1 #financing, bringing our total capital raised to $386M. Additionally, we entered an exclusive option agreement with VelaVigo to develop, manufacture & commercialize a potential first-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (#ADC) for multiple solid tumors, including metastatic urothelial #cancer.? ? Lastly, we are proud to share that Scott Lipman, MBA, has received the well-deserved promotion to Chief Business Officer. These significant milestones build on our continued momentum as we continue to build and advance a pipeline of best- or first-in-class #oncology therapies. Read the full press release here: https://bit.ly/3AMWkgs?

We are excited to be strengthening our Finance and Accounting team with the addition of our newest team members, Connie Hodder, executive director, FP&A and Jane Wang, CPA, vice president, Accounting! Welcome aboard #TeamAvenzo, Connie and Jane.?

We’re excited to introduce the new members of #TeamAvenzo, who are eager to join us in our mission to advance a pipeline of potential best-in-class oncology therapies.?Please help us in welcoming:? ? Nicole Doherty, Senior Director, Human Resources?? ? Evan Pendleton, Manager, Clinical Data Management? ? Jana Sipes, Executive Director, Quality Assurance? ? Bertha P. Peele, MBA, Associate Director, Regulatory Operations? ? Rafa Sharhan, Senior Director, Clinical Trial Supplies? ? Together, we’re striving to improve patient lives. Welcome to #TeamAvenzo!?? ? #NewHires??

Well-deserved congratulations to our Co-founder, President and CEO, Athena Countouriotis MD, for being hand-selected by Goldman Sachs as one of its Most Exceptional Entrepreneurs of 2024 this week at the Builders and Innovators Summit!??? ? This prestigious recognition highlights her dedication to innovation and leadership, exemplified by her impressive track record of growing and scaling companies throughout her career.?? ? Join us in congratulating Dr. Countouriotis on this incredible achievement! Learn more: https://bit.ly/4f5MCEr #GSInnovators??

We're thrilled to introduce three fantastic new members of #TeamAvenzo!?Join us in giving Chris Caster, Andra Levonian Fromme, and Laura S. a warm welcome. We are proud to expand our workforce and look forward to working together to develop the next generation of #oncology therapies for patients. #NewHires??

Today, we announced the appointment of Garry Nicholson to our Board of Directors!?With more than 30 years of experience in the pharmaceutical and #biotech industries, his distinguished background and deep understanding of the #oncology landscape will be invaluable as we continue to develop an innovative pipeline of potentially best-in-class therapies to fight cancers with high unmet medical needs.?? ? Read the full press release here: https://bit.ly/4epNZ0U

Join us in welcoming our new Executive Director of Clinical Operations, Jessica Crane! With her deep expertise in oncology clinical development, her insights will be incredibly valuable as we continue to develop our pipeline of next-generation therapies for #cancer patients.??

Today at #ESMO24, we’re presenting a poster highlighting our ongoing Phase 1/2 study of our potential best-in-class selective CDK2 inhibitor, AVZO-021, in advanced solid tumors. Join us or view the poster at https://bit.ly/4e5jywD to learn more about AVZO-021’s potential as both a monotherapy and combination agent for multiple types of cancer. ESMO - European Society for Medical Oncology